Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

被引:38
作者
Blum, K. A. [1 ]
Ruppert, A. S. [1 ]
Woyach, J. A. [1 ]
Jones, J. A. [1 ]
Andritsos, L. [1 ]
Flynn, J. M. [1 ]
Rovin, B. [2 ]
Villalona-Calero, M. [3 ]
Ji, J. [4 ]
Phelps, M. [4 ]
Johnson, A. J. [1 ]
Grever, M. R. [1 ]
Byrd, J. C. [1 ,4 ]
机构
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Div Nephrol, Dept Internal Med, Columbus, OH 43210 USA
[3] Arthur G James Comprehens Canc Ctr, Div Med Oncol, Dept Internal Med, Columbus, OH USA
[4] Ohio State Univ, Div Med Chem & Pharmacol, Coll Pharm, Columbus, OH 43210 USA
关键词
chronic lymphocytic leukemia; flavopiridol; tumor lysis syndrome; CONTINUOUS-INFUSION; FLUDARABINE; THERAPY; CYCLOPHOSPHAMIDE; GUIDELINES; MANAGEMENT; CONSENSUS; SCHEDULE; CANCER; CELLS;
D O I
10.1038/leu.2011.109
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In univariable analysis, female gender, greater number of prior therapies, Rai stages III-IV, adenopathy >= 10 cm, splenomegaly, del(11q), decreased albumin and increased absolute lymphocyte count, white blood cell count (WBC), beta 2-microglobulin, and lactate dehydrogenase were associated (P<0.05) with TLS. In multivariable analysis, female gender, adenopathy >= 10 cm, elevated WBC, increased beta 2-microglobulin, and decreased albumin were associated with TLS (P<0.05). With respect to patient outcomes, 49 and 44% of patients with and without TLS, respectively, responded to flavopiridol (P=0.71). In a multivariable analysis, controlling for number of prior therapies, cytogenetics, Rai stage, age and gender, progression-free survival (PFS) was inferior in patients with TLS (P=0.01). Female patients and patients with elevated b2-microglobulin, increased WBC, adenopathy >= 10cm and decreased albumin were at highest risk and should be monitored for TLS with flavopiridol. TLS does not appear to be predictive of response or improved PFS in patients receiving flavopiridol. Leukemia (2011) 25, 1444-1451; doi: 10.1038/leu.2011.109; published online 24 May 2011
引用
收藏
页码:1444 / 1451
页数:8
相关论文
共 20 条
  • [1] Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from cancer and leukemia group B study 19805
    Byrd, JC
    Peterson, BL
    Gabrilove, J
    Odenike, OM
    Grever, MR
    Rai, K
    Larson, RA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4176 - 4181
  • [2] Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
    Byrd, JC
    Waselenko, JK
    Maneatis, TJ
    Murphy, T
    Ward, FT
    Monahan, BP
    Sipe, MA
    Donegan, S
    White, CA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 791 - 795
  • [3] Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
    Byrd, JC
    Shinn, C
    Waselenko, JK
    Fuchs, EJ
    Lehman, TA
    Nguyen, PL
    Flinn, IW
    Diehl, LF
    Sausville, E
    Grever, MR
    [J]. BLOOD, 1998, 92 (10) : 3804 - 3816
  • [4] Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    Byrd, John C.
    Lin, Thomas S.
    Dalton, James T.
    Wu, Di
    Phelps, Mitch A.
    Fischer, Beth
    Moran, Mollie
    Blum, Kristie A.
    Rovin, Brad
    Brooker-McEldowney, Michelle
    Broering, Sarah
    Schaaf, Larry J.
    Johnson, Amy J.
    Lucas, David M.
    Heerema, Nyla A.
    Lozanski, Gerard
    Young, Donn C.
    Suarez, Jose-Ramon
    Colevas, A. Dimitrios
    Grever, Michael R.
    [J]. BLOOD, 2007, 109 (02) : 399 - 404
  • [5] Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
    Cairo, Mitchell S.
    Coiffier, Bertrand
    Reiter, Alfred
    Younes, Anas
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) : 578 - 586
  • [6] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    Cheson, BD
    Bennett, JM
    Grever, M
    Kay, N
    Keating, MJ
    OBrien, S
    Rai, KR
    [J]. BLOOD, 1996, 87 (12) : 4990 - 4997
  • [7] Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia
    Cheson, BD
    Frame, JN
    Vena, D
    Quashu, N
    Sorensen, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) : 2313 - 2320
  • [8] Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review
    Coiffier, Bertrand
    Altman, Arnold
    Pui, Ching-Hon
    Younes, Anas
    Cairo, Mitchell S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2767 - 2778
  • [9] TUMOR LYSIS SYNDROME FOLLOWING TREATMENT WITH 2-CHLORODEOXYADENOSINE FOR REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA
    DANN, EJ
    GILLIS, S
    POLLIACK, A
    OKON, E
    RUND, D
    RACHMILEWITZ, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (21) : 1547 - 1548
  • [10] Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner, H
    Stilgenbauer, S
    Benner, A
    Leupolt, E
    Kröber, A
    Bullinger, L
    Döhner, K
    Bentz, M
    Lichter, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) : 1910 - 1916